STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Diamyd Medical AB (STO:DIAMB)(Pink Sheets:DMYDY) with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company’s patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy. The grant allows Diamyd to expand the NTDDS technology to also target neuropathy, in addition to the Company’s development portfolio for the treatment of pain.
